Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period.
- Published In:
- The lancet. Diabetes & endocrinology, 10(12), 859-868 (2022)
- Authors:
- Haqq, Andrea M, Chung, Wendy K, Dollfus, Hélène, Haws, Robert M, Martos-Moreno, Gabriel Á, Poitou, Christine, Yanovski, Jack A, Mittleman, Robert S, Yuan, Guojun, Forsythe, Elizabeth, Clément, Karine, Argente, Jesús
- Database ID:
- RPEP-06169
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06169APA
Haqq, Andrea M; Chung, Wendy K; Dollfus, Hélène; Haws, Robert M; Martos-Moreno, Gabriel Á; Poitou, Christine; Yanovski, Jack A; Mittleman, Robert S; Yuan, Guojun; Forsythe, Elizabeth; Clément, Karine; Argente, Jesús. (2022). Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period.. The lancet. Diabetes & endocrinology, 10(12), 859-868. https://doi.org/10.1016/S2213-8587(22)00277-7
MLA
Haqq, Andrea M, et al. "Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period.." The lancet. Diabetes & endocrinology, 2022. https://doi.org/10.1016/S2213-8587(22)00277-7
RethinkPeptides
RethinkPeptides Research Database. "Efficacy and safety of setmelanotide, a melanocortin-4 recep..." RPEP-06169. Retrieved from https://rethinkpeptides.com/research/haqq-2022-efficacy-and-safety-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.